OmpA in vaccine compositions and as diagnostic targets

US9945851B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9945851-B2
Application numberUS-201715474427-A
CountryUS
Kind codeB2
Filing dateMar 30, 2017
Priority dateJun 27, 2012
Publication dateApr 17, 2018
Grant dateApr 17, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection.

First claim

Opening claim text (preview).

I claim: 1. An immunogenic composition including at least one polypeptide in a vehicle or carrier suitable for administration to a subject, wherein said at least one polypeptide consists of 5 to 19 consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85. 2. The immunogenic composition of claim 1 , wherein said at least one polypeptide does not consist of 16 consecutive residues of SEQ ID NO:84. 3. The immunogenic composition of claim 1 , wherein said at least one polypeptide is SEQ ID NO:78. 4. The immunogenic composition of claim 3 , wherein said at least one polypeptide is SEQ ID NO: 6 or SEQ ID NO: 77. 5. The immunogenic composition of claim 1 , wherein said at least one polypeptide is SEQ ID NO:81 or SEQ ID NO:85. 6. The immunogenic composition of claim 5 , wherein said at least one polypeptide is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87. 7. A method of determining if a subject has been exposed to or is infected with an obligate intracellular Anaplasmataceae bacterium selected from the group consisting of Anaplasma phagocytophilum and Anaplasma marginale , wherein said subject is suspected of having a zoonotic disease caused by an obligate intracellular Anaplasmataceae bacterium, comprising the steps of contacting a test sample from said subject, under conditions that allow polypeptide-antibody complexes to form, with a composition that includes at least one polypeptide which consists of sixteen to nineteen consecutive residues of SEQ ID NO:84 including SEQ ID NO: 85, detecting one or more polypeptide-antibody complexes in said test sample, wherein the detection is an indication that antibodies specific for Anaplasmataceae OmpA are present in the test sample, and determining said subject has been exposed to or is infected with said Anaplasmataceae bacterium if said antibodies specific for Anaplasmataceae OmpA are present in the test sample. 8. The method of claim 7 , wherein said at least one polypeptide does not consist of 16 consecutive residues of SEQ ID NO:84. 9. The method of claim 7 , wherein said at least one polypeptide is SEQ ID NO: 6 or SEQ ID NO: 77. 10. The method of claim 7 , wherein said at least one polypeptide is selected from the group consisting of SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:87. 11. The method of claim 7 , wherein said contacting and detecting steps are performed using an assay selected from the group consisting of an immunoblot and an enzyme-linked immunosorbent assay (ELISA). 12. The method of claim 7 , wherein said subject is a cow and said zoonotic disease is bovine anaplasmosis. 13. The method of claim 7 , wherein said test sample is a body fluid selected from the group consisting of blood, plasma, serum, urine, and saliva.

Assignees

Inventors

Classifications

  • Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

  • Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

  • containing a GST-tag · CPC title

  • Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

  • Poisoning, e.g. from bites or stings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9945851B2 cover?
Anaplasma Marginale surface protein OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies …
Who is the assignee on this patent?
Univ Virginia Commonwealth
What technology area does this patent fall under?
Primary CPC classification G01N33/56911. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Apr 17 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).